Related Experiment Video
Updated: Nov 19, 2025
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
TRPM5 rs886277 Polymorphism Predicts Hepatic Fibrosis Progression in Non-Cirrhotic HCV-Infected Patients
Salvador Resino1, Amanda Fernández-Rodríguez1, Daniel Pineda-Tenor2
1Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28222 Majadahonda, Spain.
Background:
TRPM5 (transient receptor potential cation channel subfamily M member 5) rs886277 polymorphism has been related to liver cirrhosis from different etiologies. The present study investigates the association of TRPM5 rs886277 polymorphism with liver fibrosis progression and cirrhosis development in chronic hepatitis C (CHC) patients.
Methods:
We conducted a retrospective study of 208 non-cirrhotic patients with CHC, who had at least two liver stiffness measurements (LSM) with a separation of 12 months (baseline LSM (LSM1) and the last LSM (LSM2)). Two outcome variables were considered: (1) LSM2/LSM1 ratio; (2) cirrhosis progression (F4; LSM ≥ 12.5 kPa). DNA genotyping was done at the CeGen using a MassARRAY platform.
Results:
The follow-up time was similar irrespective of the rs886277 genotype (46.4 months in TT genotype, 46.4 months in CT genotype, and 49.2 months in CC genotype; p = 0.649). The highest LSM increases were found in patients with CC genotype compared with TT and CT genotypes (p = 0.044 and p = 0.038, respectively). The cirrhosis progression was higher in patients with CC genotype than TT genotype (p = 0.033). Thus, the rs886277 C allele was associated with higher cirrhosis progression (adjusted odds ratio (aOR) = 2.64; p = 0.014). Moreover, rs886277 CC genotype was also related to higher values of LSM2/LSM1 ratio (adjusted arithmetic mean ratio a(AMR) = 1.31; p = 0.001) and cirrhosis progression (aOR = 4.33; p = 0.027).
Conclusions:
TRPM5 rs886277 polymorphism was associated with liver fibrosis progression and cirrhosis development among hepatitis C virus (HCV)-infected patients. Specifically, the rs886277 C allele and CC genotype were risk factors for advancing liver fibrosis and cirrhosis compared to the rs886277 T allele and CT/TT genotype, respectively.
Insights
The TRPM5 rs886277 C allele and CC genotype are linked to faster liver fibrosis progression and cirrhosis development in chronic hepatitis C patients, highlighting a genetic risk factor.
Area of Science:
- Genetics
- Hepatology
- Molecular Biology
Background:
- The TRPM5 rs886277 polymorphism is associated with liver cirrhosis from various causes.
- Investigating this polymorphism's role in chronic hepatitis C (CHC) is crucial for understanding disease progression.
Purpose of the Study:
- To examine the association between the TRPM5 rs886277 polymorphism and liver fibrosis progression in CHC patients.
- To determine if this polymorphism influences the development of cirrhosis in this population.
Main Methods:
- Retrospective analysis of 208 non-cirrhotic CHC patients with serial liver stiffness measurements (LSM).
- Genotyping of the TRPM5 rs886277 polymorphism using MassARRAY.
- Assessed outcomes included LSM changes and cirrhosis development (F4 stage).
Main Results:
- Patients with the CC genotype showed significantly higher increases in LSM and a greater risk of cirrhosis progression compared to TT/CT genotypes.
- The C allele was associated with increased cirrhosis progression (aOR=2.64) and higher LSM2/LSM1 ratios (a(AMR)=1.31).
- The CC genotype was linked to a 4.33-fold increased risk of cirrhosis progression.
Conclusions:
- The TRPM5 rs886277 polymorphism is a significant factor in liver fibrosis progression and cirrhosis development in CHC patients.
- The C allele and CC genotype represent genetic risk factors for advancing liver disease in individuals with hepatitis C virus infection.
- These findings may inform personalized risk assessment and management strategies for CHC.
